Prnewswire·2026-02-23 12:15Core Viewpoint - ADC Therapeutics has amended its royalty purchase agreement with HealthCare Royalty, enhancing strategic flexibility and reducing financial obligations related to potential change of control events [2][3]. Financial Terms - The change of control payment has been reduced from $750 million to $150 million until the end of 2027, and to $200 million thereafter [2][6]. - HealthCare Royalty will continue to receive royalties on sales by any acquirer until the original royalty cap is reached [2]. - HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, exercisable until December 31, 2030, with a lock-up period until the end of 2027 [2][3]. Product Overview - ZYNLONTA is a CD19-directed antibody drug conjugate (ADC) designed to treat adult patients with relapsed or refractory large B-cell lymphoma [5][9]. - The FDA and EMA have approved ZYNLONTA for patients after two or more lines of systemic therapy, with the potential for peak revenue in the U.S. estimated between $600 million to $1 billion annually [3][7]. Company Background - ADC Therapeutics is a commercial-stage global leader in the field of antibody drug conjugates, focusing on innovative treatments through its portfolio, including ZYNLONTA [8][10].